Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers
- Conditions
- Esophagogastric Cancer
- Interventions
- Drug: PemetrexedDrug: OxaliplatinGenetic: Germline genotyping analyses for TSERDrug: LeucovorinDrug: Fluorouracil
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2016-03-08
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT02296671
Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction
- Conditions
- Adenocarcinoma of the Esophagogastric Junction
- Interventions
- Drug: OxaliplatinDrug: EpirubicinDrug: CapecitabineDrug: 5-FUDrug: CarboplatinDrug: PaclitaxelRadiation: radiationProcedure: Biopsy
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 75
- Registration Number
- NCT02287129
- Locations
- 🇩🇪
2nd department of the Medical Clinic of the Technical University Munich, Munich, Bavaria, Germany
IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis
- Conditions
- Keratosis, Actinic
- Interventions
- Drug: 5-fluorouracilDrug: ImiquimodDrug: Ingenol mebutateProcedure: methylaminolevulinate photodynamic therapy
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 624
- Registration Number
- NCT02281682
- Locations
- 🇳🇱
Maastricht UMC, Maastricht, Limburg, Netherlands
RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).
- Conditions
- Rectal Cancer
- Interventions
- Other: Laboratory testOther: Medical history and physical examinationOther: BW and heightOther: Performance statusOther: Creatinine clearanceOther: BiomarkerRadiation: Contrasting CTOther: Adverse eventOther: HBs antigen and HCV antibodyOther: EndoscopyOther: HBs antibody and HBc antibodyDrug: L-OHP (85 mg/m2)Drug: S-1Drug: L-OHP (130mg/m2)Drug: l-LVDrug: 5-FU
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Clinical Research Support Center Kyush
- Target Recruit Count
- 110
- Registration Number
- NCT02280070
- Locations
- 🇯🇵
Kyushu University Hospital, Fukuoka, Japan
🇯🇵Kurume University Hospital, Kurume, Japan
Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer
- Conditions
- Stage IIIA Rectal CancerStage IIIC Rectal CancerStage IIA Rectal CancerSignet Ring Adenocarcinoma of the RectumMucinous Adenocarcinoma of the RectumRecurrent Rectal CancerRectal AdenocarcinomaStage IIIB Rectal CancerStage IIB Rectal CancerStage IIC Rectal Cancer
- Interventions
- Radiation: intensity-modulated radiation therapyDrug: fluorouracilDrug: oxaliplatinDrug: leucovorin calciumProcedure: therapeutic conventional surgery
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 14
- Registration Number
- NCT02270606
- Locations
- 🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
- Conditions
- Human Papilloma Virus InfectionStage III Squamous Cell Carcinoma of the OropharynxStage IVA Squamous Cell Carcinoma of the OropharynxStage IVB Squamous Cell Carcinoma of the Oropharynx
- Interventions
- Drug: paclitaxel albumin-stabilized nanoparticle formulationDrug: carboplatinRadiation: radiation therapyOther: laboratory biomarker analysisDrug: paclitaxelProcedure: quality-of-life assessmentDrug: fluorouracilDrug: hydroxyureaDrug: cisplatin
- First Posted Date
- 2014-10-07
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 62
- Registration Number
- NCT02258659
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Escalated Dose of Irinotecan in mCRC
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Genetic: UGTIA1 genotyping (7,7)Genetic: UGT1A1 genotyping (6,6)Genetic: UGTIA1 genotyping (6,7)Genetic: UGT1A1 non-genotypingDrug: bevacizumab (Avastin)Drug: irinotecanDrug: LeucovorinDrug: 5-FU
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Jaw-Yuan Wang, MD, PhD
- Target Recruit Count
- 213
- Registration Number
- NCT02256800
- Locations
- 🇨🇳
Chung-Ho Memorial Hospital, Kaohsiung Medical University:, Kaohsiung, Taiwan
A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC
- Conditions
- Colorectal Neoplasms
- Interventions
- Biological: BevacizumabDrug: 5-fluorouracilDrug: Irinotecan hydrochlorideDrug: Leucovorin calciumDrug: Oxaliplatin
- First Posted Date
- 2014-09-22
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- EPS Corporation
- Target Recruit Count
- 69
- Registration Number
- NCT02246049
- Locations
- 🇯🇵
EPS Corporation, Shinjuku, Tokyo, Japan
Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer
- Conditions
- Colorectal Neoplasm
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Isofol Medical AB
- Target Recruit Count
- 105
- Registration Number
- NCT02244632
- Locations
- 🇬🇷
251 General Airforce Hospital, Athens, Greece
🇬🇷Metropolitan General Hospital, Athens, Greece
🇳🇴Oslo University Hospital - Radiumhospitalet, Oslo, Norway
Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer
- Conditions
- Recurrent Colon CancerSignet Ring Adenocarcinoma of the ColonStage IVA Colon CancerStage IVA Rectal CancerMucinous Adenocarcinoma of the ColonMucinous Adenocarcinoma of the RectumStage IVB Colon CancerStage IVB Rectal CancerRecurrent Rectal CancerSignet Ring Adenocarcinoma of the Rectum
- Interventions
- Biological: ziv-afliberceptDrug: leucovorin calciumDrug: fluorouracilOther: laboratory biomarker analysis
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT02235324
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.